Chinese biology reagents developer CWBIO has raised 245 million yuan ($36 million) led by venture capital firm Addor Capital while Hong Kong-based Regent Pacific has agreed to acquire all shares in DLI for about HK$29.56 million ($4 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
